JMP Securities Reiterates Market Outperform on Elevation Oncology, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Silvan Tuerkcan has reiterated a Market Outperform rating on Elevation Oncology (NASDAQ:ELEV) and maintained a $7 price target.
July 15, 2024 | 1:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities analyst Silvan Tuerkcan has reiterated a Market Outperform rating on Elevation Oncology and maintained a $7 price target.
The reiteration of a Market Outperform rating and the maintenance of a $7 price target by JMP Securities is a positive signal for investors, likely boosting short-term confidence and potentially driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100